Speaking to Alvotech chief commercial officer Anil Okay and chief strategy officer Ming Li, the significance to the biosimilars developer of its recent successful US Food and Drug Administration inspection and subsequent approval for a US Humira (adalimumab) biosimilar are immediately apparent.
With Alvotech having previously been knocked back by the FDA on adalimumab due to issues with its biosimilar production plant...






